Table 1.
Clinical characteristics of the 325 SLE included patients
| n (%) or mean (SD) | |
|---|---|
| Age, years | 42.1 (13.7) |
| Female | 287 (88.3%) |
| Age at diagnosis SLE, years | 33.9 (14.3) |
| Duration SLE, years | 8.3 (8.9) |
| Antibodies | |
| aCL IgG | 63 (19.4%) |
| aCL IgM | 31 (9.5%) |
| LA | 99 (30.5%) |
| Anti- β2GP1 IgGa | 40 (14.4%) |
| Anti- β2GP1 IgMa | 12 (4.3%) |
| ANA | 315 (96.9%) |
| ENA | 181 (55.7%) |
| Anti-ds-DNA | 160 (49.2%) |
| Anti-SSA/Ro52 | 134 (41.2%) |
| Anti-SSB/La | 43 (13.2%) |
| Anti-RNP | 62 (19.1%) |
| Anti-Sm | 41 (12.6%) |
| SLE-related factors | |
| SLEDAI-2K | 5.1 (5.1) |
| SDI | 1.2 (1.3) |
| C3 low | 104 (32%) |
| C4 low | 85 (26.2%) |
| Cardiovascular risk factors | |
| Hypertension | 130 (40%) |
| Smoking | |
| Current smoker | 86 (26.5%) |
| Ever smoker | 160 (49.2%) |
| Never smoker | 165 (50.8%) |
| BMI (kg/m2) | 24 (21-28) |
| Dyslipidemia | 186 (57.2%) |
| Diabetes mellitus | 19 (5.8%) |
| Attribution of NP events | |
| Non-NP-SLE | 204 (62.8%) |
| Ischemic NP-SLE | 43 (13.2%) |
| Inflammatory NP-SLE | 78 (24%) |
aCL: anticardiolipin; β2GP1: Beta2 glycoprotein 1; BMI: body mass index; LA: lupus anticoagulant; NP: neuropsychiatric; SD: standard deviation; SDI: Systemic Lupus International Collaborating Clinics damage index; SLE: systemic lupus erythematosus; SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000.
a
Only 278 patients were assessed for B2GP IgG and IgM.